Share on StockTwits

Quest Diagnostics (NYSE:DGX) CFO Mark Guinan purchased 4,000 shares of Quest Diagnostics stock in a transaction dated Monday, May 5th. The shares were purchased at an average cost of $55.51 per share, with a total value of $222,040.00. Following the purchase, the chief financial officer now directly owns 44,222 shares in the company, valued at approximately $2,454,763. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Quest Diagnostics (NYSE:DGX) traded up 0.59% on Wednesday, hitting $55.90. The stock had a trading volume of 3,337,624 shares. Quest Diagnostics has a one year low of $50.46 and a one year high of $64.10. The stock has a 50-day moving average of $57.75 and a 200-day moving average of $56.46. The company has a market cap of $8.050 billion and a P/E ratio of 10.18. Quest Diagnostics also saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 20,253,167 shares, a decrease of 18.3% from the March 31st total of 24,797,304 shares. Currently, 14.1% of the shares of the company are sold short. Based on an average daily volume of 2,888,589 shares, the days-to-cover ratio is presently 7.0 days.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, April 24th. The company reported $0.84 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.89 by $0.05. The company had revenue of $1.75 billion for the quarter, compared to the consensus estimate of $1.75 billion. During the same quarter last year, the company posted $0.89 earnings per share. Quest Diagnostics’s revenue was down 2.3% compared to the same quarter last year. On average, analysts predict that Quest Diagnostics will post $4.02 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on DGX shares. Analysts at Credit Suisse raised their price target on shares of Quest Diagnostics from $55.00 to $62.00 in a research note on Monday, April 14th. Separately, analysts at Goldman Sachs raised their price target on shares of Quest Diagnostics from $61.00 to $67.00 in a research note on Friday, April 11th. Finally, analysts at Mizuho raised their price target on shares of Quest Diagnostics from $54.00 to $63.00 in a research note on Wednesday, April 2nd. They now have a “neutral” rating on the stock. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $59.41.

Quest Diagnostics Incorporated (NYSE:DGX), is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.